Adlai Nortye Ltd. reported that it has administered the first dose of its oral pan‑RAS inhibitor AN9025 to a patient in the United States as part of a Phase 1, first‑in‑human, multicenter, open‑label study. The dosing took place at a U.S. site in early February 2026, marking the first step in the drug’s global clinical development.
AN9025 is designed to inhibit a broad spectrum of RAS mutations, which drive a significant share of solid‑tumor cancers such as pancreatic, lung, and colorectal adenocarcinomas. By targeting the RAS pathway, the compound aims to fill a therapeutic gap that has historically been considered undruggable, positioning Adlai Nortye as a potential leader in precision oncology.
The trial is being conducted in partnership with Jiangsu Aosaikang Pharmaceutical Co. Ltd. (ASK Pharm). Under the license agreement, Adlai Nortye retains exclusive rights to AN9025 outside China, while ASK Pharm holds rights within mainland China, Hong Kong, and Macao. The split arrangement allows the company to leverage local expertise in Greater China while maintaining control of the product’s global commercialization.
Adlai Nortye’s recent financial activity includes a $140 million private placement completed on February 3 2026, which bolstered its cash position to $44.1 million. The infusion supports ongoing clinical development and positions the company to sustain its research pipeline while managing cash burn.
The announcement was met with a muted market reaction, with some investors noting an increase in short interest. The event underscores the company’s progress in a highly competitive RAS‑inhibitor landscape, where rivals such as Revolution Medicines are also advancing similar compounds.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.